Loading...
Loading...
Teva Pharmaceutical Industries Ltd.
TEVA and Perrigo Company
PRGO today announced the launch of the generic equivalent to Temodar®
(temozolomide). Teva will manufacture, market and distribute the product in
the U.S. and both companies will equally share in the cost and profitability
of the product in the U.S. Teva was first to file, making the product eligible
for 180 days of marketing exclusivity.
This product is the generic equivalent to Temodar® (temozolomide), indicated
for the treatment of adult patients with newly diagnosed glioblastoma
multiforme concomitantly with radiotherapy and then as maintenance treatment
and refractory anaplastic astrocytoma patients who have experienced disease
progression on a drug regimen containing nitrosourea and procarbazine.
Temodar® had annual sales of approximately $423 million in the United States,
according to IMS data as of December 31, 2012. The launch of this product
provides a quality alternative, making cancer therapy more cost effective for
patients who suffer from this devastating cancer.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in